Daniel Schneider
President & CEO

All right. Well, great. Welcome, everyone, to Photocure ASA's First Quarter '26 Results. I'm Dan Schneider, President and CEO. Today, with me will be Dick Peters. He's Controller for Photocure. Erik Dahl, our CFO, is out ill today. And also Priyam Shah, Vice President Investor Relations. Just a reminder, the usual disclaimers are in effect for today's presentation.

So Photocure's corporate strategy is built on 3 priorities: guiding execution and capital allocation. The first pillar is strengthening the core Hexvix and Cysview business, driving disciplined revenue and EBITDA growth while expanding operating leverage. U.S., we want to scale the Blue Light Cystoscopy Mobile ForTec along with the tower installations and upgrades with the goal of increasing BLC inactive and upgraded accounts, so increasing that throughput. And in the EU, we want to increase penetration in the key EU markets through BLC expansion, image upgrades and broader distribution reach, and we'll talk more about these today.

We also want to be a lead in the standard, establishing BLC as the primary precision diagnostic across detection, surveillance and the treatment monitoring of non-muscle invasive bladder cancer. We also support next-generation high-def BLC adoption via the OEM upgrades and new OEM entrants. As we mentioned in today's presentation, Stryker has now entered the blue light cystoscopy market in Europe, and that is extremely exciting, if you know anything about the Stryker organization. And then partner with Richard Wolf to grow flexible BLC in Europe while advancing our co-development of the 4K global Flex system for a proprietary launch in 2027 on a global scale.

And the third pillar, expanding